-

Rejuvra™ Herbicide Receives EPA Approval

New herbicide is a long-term, economical solution for the control of invasive annual grasses

CARY, N.C.--(BUSINESS WIRE)--The Vegetation Management business within Bayer CropScience LP, announces that Rejuvra herbicide was approved by the U.S. Environmental Protection Agency (EPA). The herbicide is federally registered for controlling invasive weed species on rangeland, CRP land and natural areas, including grazed areas on these sites.

Rejuvra is a pre-emergent herbicide and restoration tool that is showing consistent multi-year control of invasive annual grasses like cheatgrass-downy brome, medusahead and ventenata. With just one application, Rejuvra stops the need for yearly applications that only combat the symptom, not the problem of controlling the weed seed bank.

By controlling invasive annual grasses, remnant desirable perennial grasses and forbs can recolonize. Forage quantity and quality is improved and wildfire risk is reduced. Trial work across the western United States showed that areas treated with Rejuvra demonstrated a two-to-three-fold increase in perennial grass biomass, compared to untreated areas. A single pre-emergent application of Rejuvra provides consistent multi-year control of invasive annual grasses, reducing costs associated with time and labor.

“We are excited that Rejuvra herbicide has received approval from the EPA,” said Bayer Head of Vegetation Management Marketing, North America, Tiffany Fremder. “We are thrilled to provide ranchers and rangeland managers with an economical solution for multi-year invasive annual grass control that results in weed seed bank depletion and increased perennial grass and forb forage production.”

Documented benefits of using Rejuvra herbicide include:

  • Consistent, long-term weed control: Multi-year control of invasive annual grasses with seed bank depletion.
  • Releases and restores perennial native vegetation: Perennial plants respond quickly to the additional water and nutrients that become available when invasive annual grasses are controlled, resulting in increased perennial biomass and forage production, and restored native plant communities.
  • Improved wildlife habitat: Removes invasive winter annuals, resulting in recolonization of grass, forbs and shrubs beneficial to pollinators, birds and other wildlife.
  • Reduced wildfire risk: Decreases fine-fuels associated with wildfires.
  • Economical solution: Fewer applications are needed to control weeds, saving time and labor. Multi-year weed control with a single application can provide a greater return on investment (ROI).
  • No grazing restrictions: For application rates of five ounces per acre.

This product is not offered yet for sale. First sales of Rejuvra herbicide are anticipated in July 2020 following state registrations.

For more information on Rejuvra Herbicide, contact your local Bayer sales representative or visit: www.rejuvra.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

ALWAYS READ AND FOLLOW LABEL INSTRUCTIONS.

Bayer Environmental Science, a business unit of Bayer CropScience LP, 5000 CentreGreen Way, Suite 400, Cary, NC 27513. 1-800-331-2867. www.environmentalscience.bayer.us. Bayer, the Bayer Cross and Rejuvra are trademarks of Bayer. Not all products are registered in all states. Always read and follow label instructions carefully. ©2020 Bayer CropScience LP.

Contacts

Bayer Media Hotline, 1-862-404-5118, or

Tiffany Fremder
Head of IVM Marketing, North America
Environmental Science, a Division of Bayer CropScience
Email: tiffany.fremder@bayer.com

Erica Ballmer
Rhea + Kaiser
Email: eballmer@rkconnect.com

Bayer


Release Versions

Contacts

Bayer Media Hotline, 1-862-404-5118, or

Tiffany Fremder
Head of IVM Marketing, North America
Environmental Science, a Division of Bayer CropScience
Email: tiffany.fremder@bayer.com

Erica Ballmer
Rhea + Kaiser
Email: eballmer@rkconnect.com

More News From Bayer

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits during the Court’s 2026 session, which ends in June. “The Supreme Court decision to take the case is good news for U.S. far...

Bayer Accelerates Pharma Growth on High-Value Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash experiences and learn about treatment options, including Lynkuet® (elinzanetant) 60mg capsules, a hormone-free prescri...
Back to Newsroom